As of 2026-04-07, the Intrinsic Value of Qiagen NV (QGEN) is 38.52 USD. This QGEN valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 40.78 USD, the upside of Qiagen NV is -5.50%.
The range of the Intrinsic Value is 27.97 - 61.74 USD
Based on its market price of 40.78 USD and our intrinsic valuation, Qiagen NV (QGEN) is overvalued by 5.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 27.97 - 61.74 | 38.52 | -5.5% |
| DCF (Growth 10y) | 30.77 - 62.66 | 40.83 | 0.1% |
| DCF (EBITDA 5y) | 39.38 - 58.84 | 44.52 | 9.2% |
| DCF (EBITDA 10y) | 39.10 - 59.25 | 45.08 | 10.5% |
| Fair Value | 51.55 - 51.55 | 51.55 | 26.40% |
| P/E | 44.58 - 53.52 | 48.76 | 19.6% |
| EV/EBITDA | 40.09 - 89.09 | 59.95 | 47.0% |
| EPV | 16.47 - 21.56 | 19.01 | -53.4% |
| DDM - Stable | 16.80 - 43.98 | 30.39 | -25.5% |
| DDM - Multi | 22.70 - 46.10 | 30.41 | -25.4% |
| Market Cap (mil) | 8,403.53 |
| Beta | 0.80 |
| Outstanding shares (mil) | 206.07 |
| Enterprise Value (mil) | 9,218.96 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.40% |
| Cost of Debt | 4.25% |
| WACC | 9.42% |